About: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.99 (-0.92%)
RNAC NASDAQ Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc. share price
RNAC price activity
Last Price
$6.990
Change (24hr)
-0.07 USD (-0.92%)
Volume
97.18K
Volume (4w avg)
-
Open
$7.00
Day Range
$6.99 - $7.00
Previous Close
$7.06
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
RNAC price performance
Delayed
12 Oct, 8:00 pm GMT+0
RNAC Market Signals